Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

L. Khoja, E. G. Atenafu, S. Suciu, S. Leyvraz, T. Sato, E. Marshall, U. Keilholz, L. Zimmer, S. P. Patel, S. Piperno-Neumann, J. Piulats, T. T. Kivela, C. Pfoehler, S. Bhatia, P. Huppert, L. B. J. Van Iersel, I. J. M. De Vries, N. Penel, T. Vogl, T. ChengG. Fiorentini, F. Mouriaux, A. Tarhini, P. M. Patel, R. Carvajal, A. M. Joshua*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data.

Methods: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated.

Results: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus = 3 cm versus

Conclusion: Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may be used to facilitate future trial design and stratification in mUM.

Original languageEnglish
Pages (from-to)1370-1380
Number of pages11
JournalAnnals of Oncology
Volume30
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • meta-analysis
  • uveal melanoma
  • trial design
  • survival benchmarks
  • STAGE-IV MELANOMA
  • PHASE-II TRIAL
  • GEMCITABINE PLUS TREOSULFAN
  • LIVER METASTASES
  • CHEMOEMBOLIZATION TACE
  • CHOROIDAL MELANOMA
  • 1ST-LINE TREATMENT
  • INTRAARTERIAL
  • TEMOZOLOMIDE
  • COMBINATION

Cite this